OBJECTIVES: Osteoporotic Fractures (OF) in elderly people are common worldwide, and the predicted aging of populations is increasing the burden of OF on health care systems. This study estimates the economic burden of OF in aged 65 years and over in South Korea from a societal perspective. METHODS: National health insurance claim databases were used to analyze annual health care utilization and medical costs of OF in the South Korean population (49.78 million). We identified medical claims records for elderly people with a diagnosis of OF and estimated the costs by a macro-costing method from 2007 to 2011. RESULTS: From 2007 to 2011, there were 244,798 elderly patients with at least 1 medical insurance claim related to OF. Most patients had a single fracture (83%), while 17% of all patients had two or more. By fracture site, vertebral fracture accounted for 76.3% of all fractures, followed by 9.9% for hip fracture and 7.5% for wrist fracture. The societal cost of OF increased annually, from $83.7 million in 2007 to $141.4 million in 2011. For the societal cost of OF, direct medical cost was $134.9 million in 2011, which includes cost of treatment ($88.3 million) and long-term care ($46.6 million). The direct non-medical cost (transportation and caregiver costs) was estimated at $6.5 million in 2011. Costs associated with morbidity and mortality of OF were excluded due to the characteristics of the patients such as age, disability level and age at death. CONCLUSIONS: The results of this study indicate that the economic burden associated with OF in elderly people in Korea is considerable and is expected to rise with the predicted increases in life expectancy and the number of elderly in South Korea. Therefore, effective management of the disease is necessary to reduce the growth in the economic burden of OF. 
PMS23 DRUG USE AND COST EVALUATION IN RHEUMATOID ARTHRITIS PATIENTS

OBJECTIVES:
To describe drug use, drug switch and cost evaluation in patients with rheumatoid arthritis (RA). METHODS: Data derived from ARNO Observatory, an Italian population-based patient-centric system through record linkage of 11 million inhabitants. In a sub-cohort of 5,821,337 people, we identified 15,082 subjects with rheumatoid arthritis in 2011. Data were retrived for all these patients back to 2010 in order to esteem disease incidence. A cohort matched by sex, age and local health unit was computed to estimate differences in health costs. RESULTS: Prevalence of RA was 0.26% with an average age of 62 years and a percentage of women of 77%. Incidence is about 0.03% per year. The cost perperson is €2,823 per year, 128% more in comparison with pair-matched group. This cost is for €1,230 due to drugs (€564 specific drugs, €666 others), €1,024 due to hospitalization and €569 due to lab tests and diagnostic examinations. Most common drugs are methylprednisolone+prednisone (63% treated), methotrexate (47.2%) and hydroxychloroquine (31.6%). Biological drugs are used by 3% of patients, but this percentage is increasing by years. Patients treated with biological drugs cost three times higher than others. Patients usually start first treatment with methylprednisolone+prednisone (46.6%), 25.2% start with methylprednisolone+prednisone and other specific drugs and 12.1% with methotrexate. One year after the first treatment only 40.1% of patients continue receiving the same treatment, 41.4% add a specific drug, 11.7% leave therapy and 6.8% switch to another specific drug. CONCLUSIONS: This administrative database is an important source of information that is able to show both economical indicators and the good practice of treatment. In this study, they point out an elevated cost per-person in drugs assumption and show very current tendency to switch therapy in the first year. 
PMS24 MEDICAL COSTS OF PATIENTS WITH RHEUMATOID ARTHRITIS AND ITS ASSOCIATION WITH GLOBAL DISEASE ACTIVITY IN TURKEY
OBJECTIVES:
To identify factors associated with the cost of RA care and calculate risk-adjusted costs associated with RA in Turkey. We also examined the relationships between costs of RA treatment and global disease activity. METHODS: This cross-sectional study was performed in 10 university rheumatology centers. Eligible patients were ≥18 years of age and diagnosed with RA for at least 12 months according to the American College of Rheumatology (ACR) 1987 criteria. Generalized linear models were used to calculate riskadjusted direct costs. After using the Park test, the Gamma family with log link was chosen for the model. Age, gender, region, RA-related medication use and comorbidities such as diabetes, cardiovascular and respiratory disease, allergy and surgery were controlled in the model. Costs were adjusted by exchange rate of €1=2.30 Turkish Lira. RESULTS: A total of 698 patients (82% female; mean age: 51.2±13.17 standard deviation [SD] years) were studied. Patients' visual analog scale (VAS), patient's global disease activity (GDA) and routine assessment of patient index data 3 (RAPID-3) scores were on average 44.15, 5.19 and 5.10 respectively. Most patients were prescribed immunosuppressive medication and glucocorticoids (87.8% and 61.2%, respectively). Risk adjusted costs were estimated as €2,671. The most significant portion of overall expenditures was due to pharmaceutical costs €1987, while outpatient costs were €303, inpatient costs were €360 and co-payments were €21. 14% of patients experienced work loss due to RA. On average, annual costs due to workday loss were €480. 5.4% of patients also had other RA-related consultations, which were not covered by A222 V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) A 1 -A 2 9 8 insurance, bringing the average annual burden to €1600 for these patients. CONCLUSIONS: The annual medical cost of RA is significantly lower in Turkey relative to European estimates. With higher expenditures, there is a potential for a decrease in disease activity. Medicine, Istanbul, Turkey, 3 Gulhane Military Medical Academy, Ankara, Turkey, 4 Istanbul University Faculty of Medicine, Istanbul, Turkey, 5 Ege University, Izmir, Turkey, 6 Hacettepe University, Ankara, Turkey, 7 Pfizer Pharmaceuticals, Istanbul, Turkey, 8 STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 9 Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey OBJECTIVES: To explore the direct health care resources associated with ankylosing spondylitis (AS) in Turkey, and establish how treatment intensity, proxied by AS treatment expenditures, affects disease activity. METHODS: Medical records of 650 prevalent AS patients attending seven centers at tertiary health care institutions nationwide were examined to assess the annual direct health care costs. Eligible patients were age ≥18 and diagnosed with AS for at least 12 months. To identify direct costs, overall costs were categorized as inpatient, outpatient, pharmacy and copay. Generalized linear models were used to determine factors affecting annual health care costs. Costs were adjusted by exchange rate of €1=2.30 Turkish Lira. RESULTS: The average patient age was 40.1±11.33 standard deviation (SD) years and 35% of AS patients were female. Average disease duration was 7.9 years and more than 25% of patients suffered from at least one comorbidity. 7.54% of AS patients received inpatient care, 92.77% received outpatient care and 95.23% weAre prescribed at least one medication. 66.77% of patients were prescribed disease-modifying antirheumatic drugs (DMARDs). The mean (median) annual cost per patient was €6,059 (€6,825). The most significant portion of overall expenditures was due to drug cost (€5,728), while outpatient costs totaled €254 and inpatient costs €68. Copayments were relatively low at €12.3. Age and gender had no effect on annual health care costs. 54.92% of AS patients experienced work loss due to their condition. On average, annual cost due to work loss was calculated at €412. Two percent of patients also had other AS-related consultations, which were not covered by insurance. The average annual burden for these patients was €2482. CONCLUSIONS: Inpatient and outpatient costs for AS patients are lower in Turkey relative to other European countries. Treatment intensity inversely affects GDA, indicating that GDA can be improved by increasing treatment intensity.
PMS25 ANKYLOSING SPONDYLITIS HEALTH CARE COSTS AND ASSOCIATED DISEASE ACTIVITY SCORES IN TURKEY
PMS26
LONG-TERM COSTS OF BIOLOGICS IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES
Cure S 1 , Cawston H 2 , Damera V 1 , Tencer T 3 , Zhang F 3 1 OptumInsight, Uxbridge, UK, 2 OptumInsight, Nanterre, France, 3 Celgene Corporation, Summit, NJ, USA OBJECTIVES: The introduction of biologic therapies has dramatically changed the management of psoriatic arthritis (PsA). The study aimed to estimate longterm costs of biologics in the treatment of psoriatic arthritic patients in the United States. METHODS: We developed a 10-year Markov model describing the treatment pathway of patients with psoriatic arthritis who had failed prior oral DMARD therapy, using monthly cycles. Clinical efficacy data were obtained from published pivotal study results and literature. Costs, resource utilisation and treatment pathways were obtained from literature and expert opinion. Patients transitioned through two lines of biologics (etanercept, infliximab, golimumab or adalimumab as first or second line) followed by best supportive care. Response to therapy was defined as the probability of PsARC response at the end of the trial period. Patients transitioned to the next line of therapy in case of non-response or discontinuation due to other causes (a short-term annual drop-out rate of 32% and a long-term rate of 16.5% were assumed). Allcause death was included and adjusted to reflect the increased mortality associated with PsA. Treatment and administration, monitoring, and hospitalisation costs were included. An annual discount rate of 3% was used. Probabilistic sensitivity analysis was conducted on key model parameters. For each first-line biologic option, average results across second-line biologic therapies were reported. RESULTS: From a third-party payer's perspective, the estimated 10-year cumulative direct costs per patient were $214,642 (95% Crl: $214,171; $221,074) with etanercept as first-line biologic therapy, $203, 140 (95% CrI: $202, 632; $208, 398) with infliximab, $218, 703 (95% Crl: $217, 992; $224, 255) with golimumab and $208,840 (95% CrI: $208,192; $215,014) with adalimumab. Across scenarios, drug costs represented between 89.4% and 91.1% of total costs, monitoring costs between 4.5% and 6.3%, and hospitalisation costs between 4.3% and 4.9%. CONCLUSIONS: Biologic therapies represent a significant cost burden to payers.
PMS27 HEALTH CARE COSTS ASSOCIATED WITH FIRST-AND SECOND-LINE SWITCHING OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
